Incidence of Invasive Pulmonary Aspergillosis in Ventilator-associated Pneumonia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

263 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-08-28

Study Completion Date

2025-07-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Mechanically ventilated patients are at risk of developing ventilator-associated pneumonia (VAP). Invasive pulmonary aspergillosis (IPA), the diagnosis of which motivates the implementation of specific treatments, is one of the causes of VAP. The hypothesis of the study is that the incidence of IPA is 12.4%. For each patient presenting with a suspicion of VAP and requiring a bronchoalveolar lavage (BAL), the diagnosis of API will be evaluated by biological examinations performed on blood and BAL. Medical and surgical history as well as clinical and biological data will be collected for 28 days or until discharge from the ICU.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Invasive Pulmonary Aspergillosis Complicating Influenza Infection

NCT03391492

Influenza With Pneumonia Aspergillosis Invasive

COMPLETED

Clinical and Prognostic Comparisons Between Invasive Pulmonary Aspergillosis With or Without Invasive Tracheobronchitis During Severe Influenza: a Retrospective Multicenter Cohort Study.

NCT04077697

Invasive Pulmonary Aspergillosis Morality

COMPLETED

Influenza Associated Aspergillosis In-depth Investigation

NCT03748069

Influenza With Pneumonia Invasive Pulmonary Aspergillosis

RECRUITING

Prospective Observational Trial of IAPA

NCT04530799

Influenza With Pneumonia Pulmonary Aspergillosis

RECRUITING

Non-invasive Tools to Diagnose Invasive Aspergillosis Infections in ICU Patients With COVID-19 and Other Conditions.

NCT05138666

Invasive Pulmonary Aspergillosis

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ventilator Associated Pneumonia Pulmonary Aspergillosis Invasive

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with suspected ventilator-associated pneumonia

Biological examinations performed on blood and BAL

Intervention Type OTHER

Direct examination and culture of BAL Galactomannan in serum and BAL Serum 1,3 beta D glucans Aspergillus PCR in BAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Biological examinations performed on blood and BAL

Direct examination and culture of BAL Galactomannan in serum and BAL Serum 1,3 beta D glucans Aspergillus PCR in BAL

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patient (age ≥ 18 years),
* On invasive ventilation for more than 48 hours,
* Suspected VAP, defined by the appearance or worsening of a radiological pulmonary infiltrate, associated with 2 of the following clinical criteria:

* Fever ≥ 38° C or hypothermia ≤ 36.5° C
* Leukocytes \> 12x109 or \< 4x109/L
* Purulent tracheal secretions